Sign In
Buy LLY
$1,131.42
+6.04 (+0.537%)
At Close: Jun 05, 2026
Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease
06:45am, Monday, 08'th Jul 2024
Acquisition to expand Lilly's immunology pipeline with oral integrin therapies INDIANAPOLIS and WALTHAM, Mass. , July 8, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Morphic Holding, In
Recession Alert: Play Defense While Earning Up To 10% Yield
10:15am, Sunday, 07'th Jul 2024
Don't fear recessions; embrace them with a well-constructed portfolio. Market prices and business fundamentals are distinct elements. Focus on the latter. We discuss two picks from non-discretionary s
Eli Lilly Remains an Equities Outlier
10:13am, Friday, 05'th Jul 2024
New obesity and Alzheimer's disease treatments are keeping Eli Lilly and Company (LLY) at the forefront of equities excellence.
Big tech is not the haven some claim, so it's time to raise cash, says this hedge fund
08:40am, Friday, 05'th Jul 2024
Friday futures action suggests U.S. investors will return from the Independence Day break with stocks striving to register more record highs.
7 High Priced Stocks That Would Benefit From a Stock Split
03:45pm, Thursday, 04'th Jul 2024
Several high-profile stock splits have occurred recently. First, Nvidia (NASDAQ: NVDA ) decided to implement a 10-for-1 stock split which took effect June 10.
NVO, LLY Slip After Study Links Obesity Drug Use to Vision Loss
09:20am, Thursday, 04'th Jul 2024
A new study led by investigators of a Harvard-affiliated teaching hospital found that Novo Nordisk's (NVO) GLP-1 drugs Ozempic and Wegovy could be linked to rare cases of vision loss.
Eli Lilly Stock Price Prediction: Where Will It Be in 1 Year
09:15am, Thursday, 04'th Jul 2024
24/7 Insights Wall Street expectations for where Eli Lilly and Co.
Mounjaro and Zepbound Are Great, but This Is the Real Reason Why Eli Lilly Can Soar Past a $1 Trillion Valuation
07:30am, Thursday, 04'th Jul 2024
Zepbound and Mounjaro will add tens of billions in revenue to Eli Lilly's top line in the years ahead. But management is looking beyond those products and developing even more weight loss treatments.
The 3 Best Healthcare Stocks to Buy in July 2024
06:35am, Thursday, 04'th Jul 2024
The COVID-19 pandemic emphasized the importance of healthcare companies. Consistent breakthroughs, improved products and relatively consistent growth make these companies fan-favorite picks for invest
Weight-loss drugs linked to rare vision loss: Harvard study
05:40pm, Wednesday, 03'rd Jul 2024
Novo Nordisk (NVO) and Eli Lilly (LLY) shares dip in reaction to a Harvard study that found GLP-1 weight-loss drugs Ozempic and Wegovy could be linked to rare cases of vision loss. Yahoo Finance healt
Bullish on LLY & Bearish on INTC, LOW
01:12pm, Wednesday, 03'rd Jul 2024
Eli Lilly (LLY), Intel (INTC), and Lowe's (LOW) are today's Big Three. Don Kaufman and Ben Lichtenstein discuss the technical trends, as well as how to trades these stocks.
Novo Nordisk, Eli Lilly Tumble After Study Suggests Weight-Loss Drugs Can Lead To Blindness
12:35pm, Wednesday, 03'rd Jul 2024
Novo Nordisk stock skidded Wednesday after a new study suggests its diabetes and weight-loss drug can lead to a blindness-causing disease.
Eli Lilly's Alzheimer's Therapy's Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst
12:13pm, Wednesday, 03'rd Jul 2024
On Tuesday, the FDA approved Eli Lilly and Co's LLY Kisunla (donanemab) once-monthly injection for IV infusion) for adults with early symptomatic Alzheimer's disease.
FDA Approves Eli Lilly's Alzheimer's Drug Kisunla
11:35am, Wednesday, 03'rd Jul 2024
Eli Lilly (LLY) has received Food and Drug Administration (FDA) approval for its treatment for early symptomatic Alzheimer's after studies showed that the drug was able to slow the progression of the
Eli Lilly (LLY) Hits Highs After FDA Approves Its Alzheimer's Treatment
11:32am, Wednesday, 03'rd Jul 2024
Eli Lilly (LLY) hit a new all-time high today as the FDA approved its Alzheimer's treatment “Kisunla.” The treatment is intended for adults in early symptomatic stages of Alzheimer's disease.
